Belite Bio: Bioptima sells 500 depositary shares

The reported trades followed a Rule 10b5-1 trading plan adopted June 25, 2026, and each American depositary share represents one ordinary share.

Rhea-AI Filing Summary

Belite Bio, Inc. Chief Medical Officer Hendrik Peter Scholl reported that Bioptima Ltd. indirectly sold 500 American depositary shares on October 1, 2026. The sales were made under a Rule 10b5-1 trading plan adopted June 25, 2026. Reported per-share prices across the sale tranches ranged from $163.6250 to $170.0200; each American depositary share represents one ordinary share.

Insider Trade Summary 10b5-1

Net Seller: 500 shares

Net Sell 8 txns

Insider Scholl Hendrik Peter

Role Chief Medical Officer

Sold 500 shs ($83K)

Type	Security	Shares	Price	Value
Sale	American depositary share F1, F2, F3	200	$163.625	$33K
Sale	American depositary share F1, F2, F4	24	$164.6408	$4K
Sale	American depositary share F1, F2, F5	120	$165.4935	$20K
Sale	American depositary share F1, F2, F6	50	$166.4368	$8K
Sale	American depositary share F1, F2, F7	78	$167.5876	$13K
Sale	American depositary share F1, F2, F8	12	$168.2117	$2K
Sale	American depositary share F1, F2, F9	14	$169.36	$2K
Sale	American depositary share F1, F2	2	$170.02	$340.04

Holdings After Transaction: American depositary share — 14,500 shares (Indirect, By Bioptima Ltd.)

Footnotes (9)

1. F1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
2. F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/25/2026.
3. F3. Represents the weighted average price of shares sold at prices that ranged from $163.6 to $163.65. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
4. F4. Represents the weighted average price of shares sold at prices that ranged from $164.41 to $164.96. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
5. F5. Represents the weighted average price of shares sold at prices that ranged from $165 to $165.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
6. F6. Represents the weighted average price of shares sold at prices that ranged from $166.06 to $166.77. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
7. F7. Represents the weighted average price of shares sold at prices that ranged from $167 to $167.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
8. F8. Represents the weighted average price of shares sold at prices that ranged from $168.03 to $168.42. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
9. F9. Represents the weighted average price of shares sold at prices that ranged from $169.18 to $169.51. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

Key Figures

American depositary shares sold: 500 American depositary shares Sale tranche price: $163.6250 per share Sale tranche price: $170.0200 per share

3 metrics

American depositary shares sold 500 American depositary shares Indirect sales by Bioptima Ltd. on October 1, 2026

Sale tranche price $163.6250 per share 200-share tranche on October 1, 2026

Sale tranche price $170.0200 per share Two-share tranche on October 1, 2026

Key Terms

Rule 10b5-1 trading plan, American depositary share, weighted average price

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

American depositary share financial

"Each American depositary share represents one ordinary share"

An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.

weighted average price financial

"Represents the weighted average price of shares sold"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BLTE American depositary shares did Bioptima Ltd. sell?

Bioptima Ltd. indirectly sold 500 American depositary shares on October 1, 2026, as reported by Belite Bio, Inc. Chief Medical Officer Hendrik Peter Scholl. The sales were made under a Rule 10b5-1 trading plan adopted June 25, 2026.

What prices were reported for the BLTE share sales?

The reported per-share prices ranged from $163.6250 to $170.0200. The $163.6250 price applied to a 200-share tranche, and the $170.0200 price applied to a two-share tranche.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 07:28 PM Accepted by SEC EDGAR 10/05/2026 - 07:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scholl Hendrik Peter

(Last) (First) (Middle)

GOTTHARDSTRASSE 26

(Street)

ZUG SWITZERLAND 6300

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American depositary share(1)	10/01/2026		S(2)		200	D	$163.625(3)	14,800	I	By Bioptima Ltd.
American depositary share(1)	10/01/2026		S(2)		24	D	$164.6408(4)	14,776	I	By Bioptima Ltd.
American depositary share(1)	10/01/2026		S(2)		120	D	$165.4935(5)	14,656	I	By Bioptima Ltd.
American depositary share(1)	10/01/2026		S(2)		50	D	$166.4368(6)	14,606	I	By Bioptima Ltd.
American depositary share(1)	10/01/2026		S(2)		78	D	$167.5876(7)	14,528	I	By Bioptima Ltd.
American depositary share(1)	10/01/2026		S(2)		12	D	$168.2117(8)	14,516	I	By Bioptima Ltd.
American depositary share(1)	10/01/2026		S(2)		14	D	$169.36(9)	14,502	I	By Bioptima Ltd.
American depositary share(1)	10/01/2026		S(2)		2	D	$170.02	14,500	I	By Bioptima Ltd.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/25/2026.

3. Represents the weighted average price of shares sold at prices that ranged from $163.6 to $163.65. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

4. Represents the weighted average price of shares sold at prices that ranged from $164.41 to $164.96. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

5. Represents the weighted average price of shares sold at prices that ranged from $165 to $165.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

6. Represents the weighted average price of shares sold at prices that ranged from $166.06 to $166.77. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

7. Represents the weighted average price of shares sold at prices that ranged from $167 to $167.93. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

8. Represents the weighted average price of shares sold at prices that ranged from $168.03 to $168.42. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

9. Represents the weighted average price of shares sold at prices that ranged from $169.18 to $169.51. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

	/s/ Hendrik Peter Scholl	10/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)